Please assess the completion status of the following clinical trial:

Trial Title: An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children and adults, male or female, aged 5 to 55 years, inclusive, who have provided written informed consent.~* New or relapsed VL or prior VL treatment failure on a regimen not containing Paromomycin or AmBisome®. The diagnosis of VL must be confirmed by a parasite-positive splenic aspirate.~Exclusion Criteria:~* LFT greater than 3 times ULN ( AST, ALT, S.Bilirubin, Alkaline Phosphatase, Hb \< 4 gm/dl.~* Platelet \<40,000/ mm3~* Prothrombin Time \> 3 Sec. longer than Control.~* Creatinine \> 3 times~  * Normal Value For Male ( 0.6 to 1.1)~ * Normal Value For Female ( 0.5 to 0.9)~* Absolute Leucocyte count- \< 1,000~* HIV infection~* Abnormal audiometric and/or vestibular dysfunction~* History of renal dysfunction~* Other severe medical conditions~* History of allergy or hypersensitivity to aminoglycosides~* Treatment with a parenteral aminoglycoside within 28 days prior to randomisation~* Previous VL treatment within the past 14 days~* Previous treatment for VL with paromomycin at any time~* Pregnancy, lactation, or lack of use of contraception in women of childbearing potential

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): Paromomycin for 21 days @ 11mg/kg
- 1 (Type: EXPERIMENTAL): Paromomycin for 14 days @ 11mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).